secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2026-07-08T11:03:56+00:00
Accession:  0001628280-26-047584
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona
------------------------------------------------------------------------

- CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.
- Charles Carter appointed CFO, SVP of Finance since Oct 2024; previously CFO at CERo Therapeutics and iCAD.
- Carter receives $460k base salary, 35% target bonus, 50,000 RSUs vesting over 2 years, plus $75k bonus opportunity.
- Rona receives 12 months base salary severance, prorated 2026 bonus, COBRA for 12 months, and consulting role through Dec 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/0001628280-26-047584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/ovid-20260707.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-047584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer